Literature DB >> 18406801

Nuclear factor-kappa B repression in antiinflammation and immunosuppression by glucocorticoids.

B van der Burg1, J Liden, S Okret, F Delaunay, S Wissink, P T van der Saag, J A Gustafsson.   

Abstract

The transcription factor nuclear factor-kappaB (NF-kappaB) directs transcription of a large number of key molecules in immunological and inflammatory responses. The recently discovered inhibition of transcriptional activity of this factor by the activated glucocorticoid receptor (GR) provides a molecular basis for the potent antiinflammatory and immunosuppressive properties of glucocorticoids. This repressive activity of the GR can function independently of transcriptional activity. Because it has been shown that certain steroid receptor ligands can differentially address transactivation and transrepression functions, it may be possible to develop ligands that specifically suppress NF-kappaB activity and, as a result, are more efficient in treatment of a variety of important chronic inflammatory diseases with less severe side effects than those of currently available drugs.

Entities:  

Year:  1997        PMID: 18406801     DOI: 10.1016/s1043-2760(97)00006-4

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  7 in total

1.  VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors:  Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal:  Cell Mol Neurobiol       Date:  2014-11-13       Impact factor: 5.046

2.  Dexamethasone inhibits TRAIL- and anti-cancer drugs-induced cell death in A549 cells through inducing NF-kappaB-independent cIAP2 expression.

Authors:  Youn Seup Kim; Jae Seuk Park; Young Koo Jee; Kye Young Lee
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

3.  High constitutive NF-kappaB activity mediates resistance to oxidative stress in neuronal cells.

Authors:  F Lezoualc'h; Y Sagara; F Holsboer; C Behl
Journal:  J Neurosci       Date:  1998-05-01       Impact factor: 6.167

4.  Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): influence on disease behaviour?

Authors:  E Louis; M Peeters; D Franchimont; L Seidel; F Fontaine; G Demolin; F Croes; P Dupont; L Davin; S Omri; P Rutgeerts; J Belaiche
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

5.  VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.

Authors:  Jesse M Damsker; Laurie S Conklin; Soheil Sadri; Blythe C Dillingham; Karuna Panchapakesan; Christopher R Heier; John M McCall; Anthony D Sandler
Journal:  Inflamm Res       Date:  2016-06-03       Impact factor: 4.575

6.  VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice.

Authors:  Jesse M Damsker; Blythe C Dillingham; Mary C Rose; Molly A Balsley; Christopher R Heier; Alan M Watson; Erik J Stemmy; Roslyn A Jurjus; Tony Huynh; Kathleen Tatem; Kitipong Uaesoontrachoon; Dana M Berry; Angela S Benton; Robert J Freishtat; Eric P Hoffman; John M McCall; Heather Gordish-Dressman; Stephanie L Constant; Erica K M Reeves; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

7.  Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease.

Authors:  Christopher R Heier; Alyson A Fiorillo; Ellen Chaisson; Heather Gordish-Dressman; Yetrib Hathout; Jesse M Damsker; Eric P Hoffman; Laurie S Conklin
Journal:  Clin Transl Gastroenterol       Date:  2016-09-15       Impact factor: 4.488

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.